Kornimate/medical-research-clean huggingface dataset:
an open-label, multi-center trial in the treatment of subjects with moderate to severe plaque type psoriasis

Conditions: Psoriasis

Summary: this is a study of a new oral drug used for the treatment of psoriasis. all subjects will get active medication, there is no placebo arm.


Eligibility criteria:
inclusion criteria: * male or female of non-childbearing potential (at least 2 years post-menopausal or undergone successful surgical sterilization at least 1 year before inclusion) * presence of moderate to severe plaque psoriasis with a pasi of at least 5 exclusion criteria: * pustular, guttate or other non-plaque forms of psoriasis or psoriatic arthritis * significant coexisting hepatic, renal, or bone marrow disease, hyperlipidemia, chronic pancreatitis, osteoporosis, or a history indicating adrenal cortex dysfunction or any other serious disease (including cancer and subjects known to be hiv positive) * history of heart failure, myocardial infarction within the past six months, cardiac arrhythmia, or under treatment for heart disorders * clinically significant abnormal ecg-intervals or morphology of the ecg; qt or qtc \>470 ms in females or \>450 ms in males * use of vitamin a (\>1000 µg/day), phenytoin, carbamazepine, warfarin, rifampicin, tetracyclines, ketoconazole, itraconazole, astemizole, terfenadine, cisapride, anti-psychotics, anti-depressants, lithium, antimalarials, alpha-blocking drugs, angiotensin-converting enzyme inhibitors, cyclosporin a, glucocorticosteroids and non-steroidal anti-inflammatory drugs, non-potassium-sparing diuretics * previous use of any systemic immunomodulatory therapy (biologicals) or psoriasis vaccine * use of other systemic therapy for psoriasis (e.g. puva, systemic steroids, cyclosporin a, methotrexate, retinoids) within four weeks prior to visit 2 * use of uv therapy or excessive uv exposure or topical therapy for psoriasis other than bland emollients within two weeks prior to visit 2

Keywords: psoriasis
l-carnitine as an adjuvant treatment in acute phosphide poisoning (lc)

Conditions: Toxicity

Summary: the aim of this study was to evaluate efficacy and safety of alpha lipoic acid(ala) as an adjuvant in the management of patients with acute phosphide poisoning.

the study was carried out following approval of the research ethical committee of tanta faculty of medicine on patients admitted to the poison control unit (emergency hospitals, tanta and mansoura universities) with acute phosphide poisoning in the period from january 2016 to january 2018. a written informed consent was taken from each patient or his/her guardians (if the patient was unable to participate in the consent process). confidentiality of the data was maintained by making code numbers for each patient. the investigators planned to conduct a randomized clinical trial to evaluate efficacy and safety of lc as an adjuvant in treatment of patients with acute phosphide poisoning. fifty patients was randomized to lc or a non lc in a 1:1 ratio (25 patients in each group). lc was given iv, as a dose of 1 g/8 hours. patients was monitored and a detailed documentation of any adverse effect due to lc therapy was recorded. this intervention represented an added treatment to the existing standard of care. all patients will continue to receive standard treatment, which was determined by the attending physician who maintained clinical responsibility for all patients. it consisted of patient resuscitation, gastric decontamination (with sodium bicarbonate, and activated charcoal \[1 g/kg, orally\] in the first 6 hours after onset of poisoning), adequate hydration and supportive treatment. all the patients was followed up until discharge or death. all patients was subjected to: i. history. ii. clinical examination. iii. laboratory investigations: at admission and repeated before discharge.

Eligibility criteria:
inclusion criteria: * patients (male or female, aged 12 years or older) with symptomatic acute phosphide poisoning (deliberate or accidental), with diagnosis made on the basis of: the typical clinical manifestations due to and following shortly after a single exposure to phosphide. reliable identification of the compound based on the container brought by patient attendants or a subsequent confirmation by silver nitrate test for phosphine detection in stomach contents. exclusion criteria: * patients less than 12 years of age pregnant and lactating women patients with ingestion or exposure to other substances in addition to phosphide. patients with other major medical conditions (e.g. cardiovascular disease, renal or hepatic failure). patients presenting more than 6 hours of having consumed the phosphide compound (late presenters). patients treated for acute phosphide poisoning in any medical center before admission

Keywords: phosphide; poisoning; l-carnitine; oxidative stress
tacrolimus (fk506) study in moderate to severe refractory ulcerative colitis patients

Conditions: Ulcerative Colitis

Summary: this study consists of a 2-week placebo-controlled double-blind inter-group efficacy study in moderate to severe refractory ulcerative colitis (uc) patients followed by a maximum of 12-week open-label efficacy and safety study in responders.


Eligibility criteria:
inclusion criteria: * moderate to severe refractory uc patients * disease activity: more than 4 times of stool a day, bloody stool, moderate to severe endoscopic finding * steroid resistance or dependence to meet at least one of the following condition:no efficacy with more than 40mg/day or 1mg/kg/day of steroid over at least 1 week, no efficacy with 30-40mg/day of steroid over at least 2 weeks,exacerbation along with steroid reduction exclusion criteria: * mild or fulminant type * renal failure patients, hepatic failure patients * patients taking 6-mercaptopurine, cyclosporin or other immunosuppressants within 12 weeks prior to entry * patients who received lcap or gcap within 2 weeks prior to entry * patients who changed the dose of steroid or started steroid within 2 weeks prior to entry. * patients who changed the dose of steroid or started steroid within 1 week prior to entry in case they received more than 40 mg/ day or 1mg/kg/day of steroid just before the study.

Keywords: ulcerative colitis tacrolimus fk506 treatment outcome
confidence financial education for caregivers

Conditions: Caregiver Burden; Financial Stress; Dementia; Alzheimer Disease

Summary: the purpose of this study is to determine how feasible it is to deliver an online course to reduce out-of-pocket costs of caregiving and reduce financial stress among latino family caregivers to a family member living with dementia. the investigators hope that that the results of this study will help to reduce high these out-of-pocket costs and improve financial wellbeing for latino family caregivers. caregivers will be asked to to participate in 3 online surveys, in addition to participating in 5, 1.5 hour group-based zoom learning sessions.


Eligibility criteria:
inclusion criteria: * caregiver to someone diagnosed by a physician with probably alzheimer's disease or a related dementia at least 6 months ago * latino or hispanic ethnicity * at least 50 years of age of older * able to attend 5, 1.5 hour to 2 hour group-based lessons over 5 weeks * no plans to place family member in a facility within the next 3 months exclusion criteria: * unreliable access to email, a computer and internet access * does note speak and read english * previously participated in confidence program

Keywords: out-of-pocket costs behavioral intervention hispanic latino self-efficacy
short-term functional recovery between early- and late bisphosphonate treatment following hemiarthroplasty

Conditions: Osteoporotic Fractures; Femoral Neck Fracture

Summary: femoral neck fracture in the elderly is one indication for initiating osteoporosis treatment. bisphosphonates remain the first line therapy; however, many orthopaedic surgeons concern regarding their effects on fracture healing process. therefore, therapy is usually delayed for a period of time. to the best of our knowledge, there is no scientific data to support whether bisphosphonate treatment should be given immediately after the surgery or it should be delayed.

femoral neck fracture in the elderly is one indication for initiating osteoporosis treatment. bisphosphonates remain the first line therapy; however, many orthopaedic surgeons concern regarding their effects on fracture healing process. therefore, therapy is usually delayed for a period of time. to the best of our knowledge, there is no scientific data to support whether bisphosphonate treatment should be given immediately after the surgery or it should be delayed. this study aims to compare functional recovery between early- and late administration of bisphosphonate in patients who received hemiarthroplasty following femoral neck fractures.

Eligibility criteria:
inclusion criteria: * patient diagnosed with femoral neck fracture and was treated with bipolar hemiarthroplasty * age more than 50 years old and bone mineral density (bmd) was in osteoporotic (t-score less than -2.5) or osteopenic (t-score between -1.0 and -2.5) ranges exclusion criteria: * patients who were treated with bipolar hemiarthroplasty for more than 2 weeks * patients with postoperative complications which affect the postoperative rehabilitation program e.g. intraoperative cracking or fracture, postoperative cardiac complication * have contraindications for bisphosphonates use e.g. renal insufficiency (glomerular filtration rate (gfr) \< 30 ml/min), allergy to bisphosphonates, severe esophagitis, gastroesophageal reflux disease etc. * patients with conditions/disorders which have an affect on bone mineral density or bone metabolism e.g. renal insufficiency, rheumatoid arthritis, paget's disease, renal osteodystrophy, hyperparathyroidism, glucocorticoids use etc. * history of bisphosphonates use within 12 months * open fracture, multiple fracture or multiple trauma patients * pathological fracture * bilateral lower extremity fractures * the pre-injury functional status of the patients is non-ambulatory

Keywords: osteoporosis femoral neck fracture hemiarthroplasty
perineural steroids for peripheral nerve blocks

Conditions: Osteoarthritis, Knee

Summary: this study will look at the efficacy of dexamethasone for prolongation of peripheral nerve blocks.

the purpose of this randomized, double-blinded, placebo-controlled trial is to examine if dexamethasone given perineurally as an adjuvant to the nerve block will prolong the time to recovery from sensory nerve block from a saphenous (or adductor canal) nerve block. the primary outcome will be time to resolution of the nerve block as assessed by pinprick over the saphenous nerve distribution. if this primary end point is met, this study will also serve as an equivalency dosing study comparing 1 mg of perineural dexamethasone to 4 mg of perineural dexamethasone.

Eligibility criteria:
inclusion criteria: * elective robotic medial mako partial knee arthroplasty * agreed to a regional anesthesia technique exclusion criteria: * contraindications to regional anesthesia * presence of a progressive neurological deficit * a pre-existing coagulopathy, infection * insulin and non-insulin dependent diabetes mellitus * systemic use of corticosteroids within 30 days of surgery * chronic use of an opioid analgesic (\>3 months or a combined total of more than 40 mg oxycodone equivalents a day) * pregnancy * a prior history of an adverse event (for example: psychosis) or an allergy to dexamethasone

Keywords: anesthesia anesthesia, conduction anesthesia, local bupivacaine dexamethasone saphenous adductor canal nerve block analgesia preanesthetic medication perioperative period peripheral nerve block
dexamethasone as adjuvant for pre - emptivetransversusabdominus muscle plane block

Conditions: Post Operative Pain

Summary: pain following bariatric surgery can be quite troublesome and prolongs recovery. although laparoscopic bariatric surgery is minimally invasive and involves small incisions over the anterior abdominal wall, postoperative pain is frequent . most morbidly obese patients also have obstructive sleep apnea and associated with cardiac co-morbidities. prolonged postoperative pain in them may lead to delay in early ambulation and performing deep breathing exercises.

pain following bariatric surgery can be quite troublesome and prolongs recovery. although laparoscopic bariatric surgery is minimally invasive and involves small incisions over the anterior abdominal wall, postoperative pain is frequent. this this increases incidence of deep vein thrombosis and risk of pulmonary complications respectively. because postoperative recovery is directly associated with the intensity and duration of pain, it is imperative to reduce the postoperative pain as early as possible. a substantial component of pain experienced by patients undergoing laparoscopic surgery is somatic pain arising from the port sites over the abdominal wall. many methods have been suggested for reducing the postoperative abdominal wall pain such as port site instillation of local anesthetics, patient-controlled analgesia (pca), epidural catheterization, and use of non-steroidal anti-inflammatory drugs (nsaids). opioid analgesics to counter immediate acute postoperative pain are known to cause postoperative nausea and vomiting (ponv). the average reported incidence of ponv in immediate postoperative period in patients undergoing bariatric surgery is between 30 and 50% \[5\]. this contributes to increased costs, increased length of stay, increased perioperative morbidity, and prolonged overall recovery \[6\]. systemically administered opioids also depress respiratory drive, level of consciousness, and supraglottic airway muscle tone resulting in hypoxia and hypercapnia. the transversusabdominis plane (tap) block is a loco-regional analgesia technique that consists of infiltrating a local anesthetic solution between the plane of the transversus-abdominis muscle and the internal oblique muscle, laterally at the level of the triangle of petit. the sensory nerves of the abdominal wall pass through this plane. this technique produces long-lasting analgesia, between 24-36 hours.

Eligibility criteria:
inclusion criteria: - 40 patients with american society of anesthesiologists (asa) grade i to ii, 20 to 65 years of age scheduled for laparoscopic sleeve gastrectomy. exclusion criteria: * patient refusal. * chronic alcoholism * chronic opioid usage * asa grade 4 or more * chronic kidney disease * chronic liver disease * chronic obstructive pulmonary disease. * known allergy to study medications. * pregnancy.
study to evaluate the efficacy, safety, and tolerability of pxt002331 (foliglurax) in reducing levodopa-induced dyskinesia and wearing off in subjects with parkinson's disease experiencing motor complications of levodopa therapy (attuned)

Conditions: Parkinson Disease

Summary: this is a multi-center, double-blind, randomized, placebo-controlled, parallel-arm phase iia proof of concept in subjects with pd treated with a stable dose of levodopa who are experiencing motor complications of levodopa therapy


Eligibility criteria:
inclusion criteria: * between 35 and 85 years of age, inclusive, at the time of signing informed consent * diagnosed after the age of 30 years with idiopathic pd * a documented medical history of idiopathic pd for at least 3 years * disease severity of 2 to 4 on the modified hoehn and yahr scale when in the off state * been treated with a stable regimen of levodopa-containing therapy * subjects must be receiving at least 3 doses per day of levodopa-containing therapy, and must be on a stable dose for at least 2 weeks for immediate-release levodopa or at least 6 weeks for prolonged-release levodopa preparations prior to the first screening visit * experienced lid over a period of at least 3 months prior to randomization * if needed, in the opinion of the investigator, subjects must have a caregiver * female subjects will be women of non-childbearing potential exclusion criteria: * patient is currently participating in or has participated in another study in the last 3 months * subjects with atypical, secondary, or drug-induced parkinsonism * subjects with a history of dyskinesia that was exclusively diphasic, off state, myoclonic, dystonic, or akathetic without peak-dose dyskinesia * subjects with a moca score of \<25 * subjects who have, or who had a history of, any clinically significant hepatic or gallbladder disorder, as determined by the investigator * subjects who have dementia, currently active psychosis, or hallucinations. * suicide attempt within 1 year prior to the first screening visit, or severe suicidal ideation within 6 months prior to the first screening visit * subject has a current diagnosis of epilepsy, * any known contraindication to the use of levodopa, including a history of malignant melanoma or a history of narrow-angle glaucoma * carcinoma or successfully treated squamous cell carcinoma of the skin and no sing of disease recurrence for at least 5 years * subjects who have had a clinically significant illness within 4 weeks before the first dose, as determined by the investigator * subjects with scheduled surgeries/hospitalizations during the study period * any advanced, severe, or unstable disease (other than pd) that may interfere with the primary and secondary study outcome evaluations * subjects who have undergone prior neurosurgical operation for pd, * subjects currently taking (or expected to be administered during the course of the study) any of the prohibited medications (amantadine, safinamide, dopamine-antagonists).

Keywords: levodopa-induced dyskinesia (lid) foliglurax parkinson's disease mglu4 pam
the effect of fetal gender on maternal substance abuse treatment

Conditions: Drug Dependence; Pregnancy

Summary: previous studies by this team of investigators has determined that male infants are more likely to display more severe neonatal abstinence syndrome (nas) as a result of maternal opioid use during pregnancy (jansson, 2007)and there is appears to be a gender-related biologic vulnerability to nas expression (jansson, 2009, submitted). the proposed study explores the relationship between fetal gender and substance abuse treatment outcomes among a population of women in comprehensive substance abuse treatment to explore the possibility of a psychosocial vulnerability among drug exposed male fetuses as opposed to female fetuses. women in substance abuse treatment are a group at high risk for current exposure to violence, usually at the hands of significant others, and having a history of sexual abuse as a child, usually resulting from contact with a male family member. therefore, they often have difficult relationships with men. at the center for addiction and pregnancy (cap), a 2006 study revealed that among a group of 715 pregnant women, reports of the exposure to violence was very high. their rates of lifetime abuse ranged from 72.7% for physical abuse to 44.5% for sexual abuse. rates of abuse remained high during their current pregnancy, ranging from 20% for physical abuse to 7.1% for sexual abuse (velez, 2006). the abuse was very often at the hands of partners or other male family member perpetrators. we hypothesize that women carrying male fetuses will be less likely to remain complaint in drug treatment or abstinent from illicit drug use, while women carrying female fetuses may be more likely to remain drug abstinent and treatment compliant. if supported, this theory has the potential to inform fetal gender specific treatment for pregnant drug dependent women. additionally, we seek to support the previously documented link between male gender and more severe expression of nas, and explore the relationship between other maternal prescribed drug use (i.e. psychotropic medications) and severity of nas expression.


Eligibility criteria:
inclusion criteria: * all cap clients who either experience a pregnancy loss, or deliver an infant while in treatment at cap between the years 7/1/03 and 6/30/08 exclusion criteria: * all cap clients who depart cap treatment prior to pregnancy loss or birth during that time period

Keywords: drug dependence during pregnancy
the effect of probiotics on the immune status, diarrhea and bacterial vaginosis cure rate among hiv patients

Conditions: HIV Infections; Diarrhea; Bacterial Vaginosis

Summary: the purpose of this study is to asses whether probiotics lactobacillus rhamnosus (gr-1) and reuteri (rc-14) are able to prevent diarrhea, delay the decline of the immune system and prevent and/or cure bacterial vaginosis among hiv patients.

background: two third of all people infected with hiv live in sub-saharan africa. a region also affected with a great burden of other infectious diseases. relatively few patients have access to anti-retroviral treatment and many suffer from debilitating diarrhea that causes their immune system to deteriorate. prevention of infectious diseases among hiv patients is of great importance and makes the immune system deteriorate less rapidly. the track record for probiotics to prevent and alleviate infectious diarrhea is impressive. so, the use of probiotics among hiv patients is a logical step and could be an adjunctive tool for physicians to halt the decline of the cd4 count. another important application for the use of probiotics is in the treatment of bacterial vaginosis (bv). bv is a vaginal infection, caused by a group of pathogens, which is extremely common, and estimated to occur in 50% of black african women. in the us, the prevalence is 29%, which again is extremely high. this infection makes a woman more vulnerable to contracting sexually transmitted infections, including hiv. having bv is also a risk factor to transmit hiv to a partner or a newborn. conventional antibiotic treatment of bv has a cure rate of 40% among black african women. a recent study shows that combining the probiotic strains lactobacillus rhamnosus gr-1 and lactobacillus reuteri rc-14 with an antibiotic has a cure rate of 88%.

Eligibility criteria:
inclusion criteria: * confirmed hiv infection. * participant does not meet the criteria for arv therapy, cd4 count \> 200, no clinical stage 3 or 4 \[national guidelines, 2005\]. * having an intermediate nugent score (4-6), or a positive nugent score (7-10). exclusion criteria: * pregnancy or lactating. * menstruation at time of diagnosis. * hypersensitive to metronidazole/warfarin/lithium/disulfiram. * not willing to avoid alcohol use during the metronidazole treatment of 10 days.

Keywords: probiotics hiv aids diarrhea lactobacillus rhamnosus gr-1 lactobacillus reuteri rc-14 immune system infectious diseases complementary therapies treatment naive